PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29588478-6 2018 DC and monocytes from patients with IKZF1 deficiency or lenalidomide-treated cultures secrete less IFN-alpha, TNF and IL-12. Lenalidomide 56-68 tumor necrosis factor Homo sapiens 110-113 32761232-4 2020 Both lenalidomide and pomalidomide dose-dependently inhibited interleukin-12 (IL-12) and TNF production and STAT4 expression, and enhanced IL-10 production in response to LPS. Lenalidomide 5-17 tumor necrosis factor Homo sapiens 89-92 32373374-5 2020 Lenalidomide, an immunosuppressant, inhibits TNF. Lenalidomide 0-12 tumor necrosis factor Homo sapiens 45-48 25287778-8 2015 In co-culture assays, TNF-alpha directly increased NK cell activation and myeloma cell death with elotuzumab or elotuzumab plus lenalidomide, and neutralizing TNF-alpha decreased NK cell activation and myeloma cell death with elotuzumab. Lenalidomide 128-140 tumor necrosis factor Homo sapiens 22-31 28983059-9 2017 Moreover, in peripheral blood mononuclear cells from patients with myelodysplastic syndromes, lenalidomide significantly reduced steady-state S100A9 generation (P=0.01) and lipopolysaccharide-induced tumor necrosis factor-alpha elaboration (P=0.002). Lenalidomide 94-106 tumor necrosis factor Homo sapiens 200-227 28983059-11 2017 Moreover, baseline serum tumor necrosis factor-alpha concentration was significantly higher in responders to erythroid-stimulating agents (P=0.03), whereas lenalidomide responders had significantly lower tumor necrosis factor-alpha and higher S100A9 serum concentrations (P=0.03). Lenalidomide 156-168 tumor necrosis factor Homo sapiens 204-231 25448491-0 2015 Increased serum tumor necrosis factor alpha levels in patients with lenalidomide-induced hypothyroidism. Lenalidomide 68-80 tumor necrosis factor Homo sapiens 16-43 25448491-4 2015 We found a significantly higher rate of therapy-induced hypothyroidism in the DLBCL-len group (25.8% vs. 1.3%), and we found a statistically significant increase in serum tumor necrosis factor alpha in patients with lenalidomide-induced hypothyroidism. Lenalidomide 216-228 tumor necrosis factor Homo sapiens 171-198 27465366-8 2016 Finally, using lenalidomide (an inhibitor of TNF-alpha), a lower viral load was found in animals with lenalidomide. Lenalidomide 15-27 tumor necrosis factor Homo sapiens 45-54 27465366-8 2016 Finally, using lenalidomide (an inhibitor of TNF-alpha), a lower viral load was found in animals with lenalidomide. Lenalidomide 102-114 tumor necrosis factor Homo sapiens 45-54 24757092-0 2014 Lenalidomide-based maintenance therapy reduces TNF receptor 2 on CD4 T cells and enhances immune effector function in acute myeloid leukemia patients. Lenalidomide 0-12 tumor necrosis factor Homo sapiens 47-50 23636891-4 2013 Modulation of TNF-alpha expression, either by stimulation using myeloid-related protein (MRP8) or lipopolysaccharide or inhibition using lenalidomide on astrocytes, leads to similar dynamic changes in miR-155 expression. Lenalidomide 137-149 tumor necrosis factor Homo sapiens 14-23 24482747-4 2013 In particular, lenalidomide has been shown to stimulate the cytotoxic functions of T lymphocytes and natural killer cells, to limit the immunosuppressive impact of regulatory T cells, and to modulate the secretion of a wide range of cytokines, including tumor necrosis factor alpha, interferon gamma as well as interleukin (IL)-6, IL-10, and IL-12. Lenalidomide 15-27 tumor necrosis factor Homo sapiens 254-281 23632478-8 2013 CONCLUSION: Lenalidomide favours a uniform TNF-alpha and IL-8 inflammatory and IGF-1 secretory profile of myeloma cells, an observation that raises important questions for therapeutic approaches incorporating the agent. Lenalidomide 12-24 tumor necrosis factor Homo sapiens 43-52 22488443-5 2012 Given the high serum and plasma levels of VEGF observed in POEMS patients, the use of anti-angiogenetic drugs such as thalidomide and lenalidomide and other drugs with anti-VEGF and anti-TNF effect such as bortezomib have been considered to treat this syndrome. Lenalidomide 134-146 tumor necrosis factor Homo sapiens 187-190 22608605-2 2012 Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. Lenalidomide 161-173 tumor necrosis factor Homo sapiens 56-77 22608605-2 2012 Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. Lenalidomide 161-173 tumor necrosis factor Homo sapiens 79-82 22608605-2 2012 Our data demonstrate that changes in genes involved the tumor necrosis factor (TNF) signaling pathway and the bone marrow stroma, suggesting that treatment with lenalidomide may help restore the damaged niche and suppress the TNF signaling pathway. Lenalidomide 161-173 tumor necrosis factor Homo sapiens 226-229 22608605-5 2012 RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. Lenalidomide 15-27 tumor necrosis factor Homo sapiens 61-82 22608605-5 2012 RESULTS: After lenalidomide treatment, genes involved in the tumor necrosis factor (TNF) signaling pathway that were upregulated in the patients before treatment decreased to the healthy control baseline expression level. Lenalidomide 15-27 tumor necrosis factor Homo sapiens 84-87 22997574-3 2012 Lenalidomide has the potential to invoke changes in TNF-alpha with less toxicity than thalidomide. Lenalidomide 0-12 tumor necrosis factor Homo sapiens 52-61 22997574-4 2012 This pilot study evaluated lenalidomide at reduction of TNF-alpha and improvement of behavior and language in children with autism with elevated TNF-alpha. Lenalidomide 27-39 tumor necrosis factor Homo sapiens 56-65 22997574-4 2012 This pilot study evaluated lenalidomide at reduction of TNF-alpha and improvement of behavior and language in children with autism with elevated TNF-alpha. Lenalidomide 27-39 tumor necrosis factor Homo sapiens 145-154 22997574-5 2012 Subjects with elevated TNF-alpha were given 2.5 mgs lenalidomide daily for 12-weeks. Lenalidomide 52-64 tumor necrosis factor Homo sapiens 23-32 17369076-5 2007 The thalidomide analogs, lenalidomide (CC-5013; Revlimid) and CC-4047 (Actimid), have enhanced potency as inhibitors of TNF-alpha and other inflammatory cytokines, as well as greater capacity to promote T-cell activation and suppress angiogenesis. Lenalidomide 25-37 tumor necrosis factor Homo sapiens 120-129 21812019-0 2011 Inflammation, TNFalpha and endothelial dysfunction link lenalidomide to venous thrombosis in chronic lymphocytic leukemia. Lenalidomide 56-68 tumor necrosis factor Homo sapiens 14-22 21812019-10 2011 In patients with lenalidomide-related DVTs, TNFalpha, and sVCAM-1 were more strongly upregulated than in all other patients (p < 0.05) and TNFalpha and sVCAM-1 levels were significantly correlated (r = 0.65, p < 0.001). Lenalidomide 17-29 tumor necrosis factor Homo sapiens 44-52 21812019-10 2011 In patients with lenalidomide-related DVTs, TNFalpha, and sVCAM-1 were more strongly upregulated than in all other patients (p < 0.05) and TNFalpha and sVCAM-1 levels were significantly correlated (r = 0.65, p < 0.001). Lenalidomide 17-29 tumor necrosis factor Homo sapiens 142-150 21812019-11 2011 These data link lenalidomide associated DVTs with TNFalpha upregulation and endothelial cell dysfunction and suggest that aspirin may have a role for DVT prophylaxis in these patients. Lenalidomide 16-28 tumor necrosis factor Homo sapiens 50-58 21215621-1 2011 Several thalidomide analogues were synthesized and compared to thalidomide and its more active analogue, lenalidomide, for their ability to inhibit the production of the pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha and interleukin (IL)-6 by LPS-activated peripheral blood mononuclear cells (PBMCs). Lenalidomide 105-117 tumor necrosis factor Homo sapiens 196-230 22010965-7 2011 Cytokine analysis showed increase in levels of TNF-alpha post-lenalidomide treatment, consistent with acute inflammatory reaction. Lenalidomide 62-74 tumor necrosis factor Homo sapiens 47-56 23556075-9 2011 Correlative studies and/or retrospective analysis of lenalidomide-treated patients had identified several biomarkers associated with clinical endpoints in CLL (i.e. changes in tumor necrosis factor alpha [TNF-alpha] or vascular endothelial growth factor [VEGF] levels) or DLBCL (non-GCB phenotype) patients, but need to be validated. Lenalidomide 53-65 tumor necrosis factor Homo sapiens 176-203 23556075-9 2011 Correlative studies and/or retrospective analysis of lenalidomide-treated patients had identified several biomarkers associated with clinical endpoints in CLL (i.e. changes in tumor necrosis factor alpha [TNF-alpha] or vascular endothelial growth factor [VEGF] levels) or DLBCL (non-GCB phenotype) patients, but need to be validated. Lenalidomide 53-65 tumor necrosis factor Homo sapiens 205-214 17168657-4 2006 It seems that lenalidomide and CC-4047 are more powerful in inhibiting TNFalpha and have, except for myelosuppression, less side effects than Thal. Lenalidomide 14-26 tumor necrosis factor Homo sapiens 71-79 34952465-10 2022 In vivo study showed that lenalidomide inhibited pro-inflammatory cytokines TNF-alpha and IL-6 while enhanced anti-fibrotic cytokines IFN-gamma and IL-10 in bleomycin-induced inflammation model, and attenuated pulmonary fibrosis and collagen deposition in the following fibrosis stage. Lenalidomide 26-38 tumor necrosis factor Homo sapiens 76-85 35586751-7 2022 Moreover, we speculate that lenalidomide improves cognitive function by regulating intracranial inflammation via multiple pathways, not only by TNF-alpha blocking. Lenalidomide 28-40 tumor necrosis factor Homo sapiens 144-153